Call for Proposals: 2022 Pfizer CTI

Pfizer is seeking proposals for the advancement of therapeutics in the following rare renal disorders: Polycystic Kidney Disease, Alport Syndrome, Focal Segmental Glomerulosclerosis & IgA Nephropathy

Open for Submissions: April 25th – June 13th, 2022


Submissions invited for novel target concepts and therapeutic strategies to slow renal decline. Examples of potential mechanisms for diseases of interest include:

Areas of Interest and Targets/Pathways of Focus:

  1. Focal Segmental Glomerulosclerosis
  2. Alport Syndrome (X-linked Autosomal Dominant)
  3. IgA Nephropathy
  4. Polycystic Kidney Disease (Autosomal Dominant and Autosomal Recessive)

Technologies and Enabling Infrastructure:

  1. Small molecules, bio-therapeutics, gene therapy
  2. Nanoparticle delivery to the kidney and kidney specific compartments and cell types
  3. RNA elements driving renal specific expression
  4. AAV Tropism specific to kidney

Out of Scope:

  1. Cell-based therapies, broad hemodynamic modifiers, complement inhibitors
  2. Standalone biomarker assays/platforms, medical device
  3. Mechanisms specifically targeting non-renal manifestation of disease
  4. Drug repurposing

Submission Process: Develop a 2–3-page non-confidential summary outlining the scientific background and research synopsis. Connect with the Pfizer contact listed who will review and provide useful guidance on your proposal prior to submission.

Request for Proposals

Information For...